These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 10169385)

  • 1. Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism.
    Anderson DR; O'Brien BJ
    Pharmacoeconomics; 1997 Jul; 12(1):17-29. PubMed ID: 10169385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty.
    Freedman KB; Brookenthal KR; Fitzgerald RH; Williams S; Lonner JH
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):929-38. PubMed ID: 10901307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures.
    Handoll HH; Farrar MJ; McBirnie J; Tytherleigh-Strong G; Milne AA; Gillespie WJ
    Cochrane Database Syst Rev; 2002; (4):CD000305. PubMed ID: 12519540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures.
    Handoll HH; Farrar MJ; McBirnie J; Tytherleigh-Strong G; Awal KA; Milne AA; Gillespie WJ
    Cochrane Database Syst Rev; 2000; 2002(2):CD000305. PubMed ID: 10796339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty.
    Anderson DR; O'Brien BJ; Levine MN; Roberts R; Wells PS; Hirsh J
    Ann Intern Med; 1993 Dec; 119(11):1105-12. PubMed ID: 8239230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
    Menzin J; Colditz GA; Regan MM; Richner RE; Oster G
    Arch Intern Med; 1995 Apr; 155(7):757-64. PubMed ID: 7695464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
    O'Brien BJ; Anderson DR; Goeree R
    CMAJ; 1994 Apr; 150(7):1083-90. PubMed ID: 8137188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge.
    Colwell CW; Collis DK; Paulson R; McCutchen JW; Bigler GT; Lutz S; Hardwick ME
    J Bone Joint Surg Am; 1999 Jul; 81(7):932-40. PubMed ID: 10428124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison.
    Garcia-Zozaya I
    J Ky Med Assoc; 1998 Apr; 96(4):143-8. PubMed ID: 9577110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DVT and pulmonary embolism: Part II. Treatment and prevention.
    Ramzi DW; Leeper KV
    Am Fam Physician; 2004 Jun; 69(12):2841-8. PubMed ID: 15222649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin.
    Bergqvist D; Lindgren B; Mätzsch T
    Br J Surg; 1996 Nov; 83(11):1548-52. PubMed ID: 9014669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalteparin: a low-molecular-weight heparin.
    Howard PA
    Ann Pharmacother; 1997 Feb; 31(2):192-203. PubMed ID: 9034422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement.
    Hawkins DW; Langley PC; Krueger KP
    Am J Health Syst Pharm; 1997 May; 54(10):1185-90. PubMed ID: 9161627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
    Dranitsaris G; Stumpo C; Smith R; Bartle W
    Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials.
    Eikelboom JW; Quinlan DJ; Douketis JD
    Lancet; 2001 Jul; 358(9275):9-15. PubMed ID: 11454370
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.